credentis ag announces successful closing of B-round financing

Please login or
register
11.03.2013

Medtech company credentis ag announces a first closing of its B-round financing. Investments currently amount to a minimum of 1.59 Mio CHF. The capital enables the company to launch a first product in different markets and to complete the development of a second one.

The investments of CHF1.59 Mio were made solely by management and existing investors including cantonal banks ZKB and AKB, StartAngels Network, BioBAC Angels, and a number of private investors including known dentists and exponents of the dental industry. “The new capital will allow us to start launching Curodont Repair and complete the development of Curodont Protect, the second product with the Curolox Technology”, says credentis CEO Dr Dominik Lysek.
 
Curolox Technology is based on peptides self-assembling into a matrix triggering the body’s own tooth regeneration and repair mechanism. Curolox is the basis for all of credentis’ products incl. Curodont Repair, for which credentis has obtained market approval (CE-label).
 
Curodont Repair provides dentists with a novel technology to regenerate rather than repair carious and similar tooth lesions. Applied to an early lesion, Curodont-Repair forms a scaffold of small fibres within the lesion around which new enamel or dentin can form and grow. Ideally, within several weeks the lesion will regenerate without the use of burr or filler. This effect is observed in a growing number of patients both in clinical studies and daily practice settings.
 
Curodont Protect uses the same technology to protect the tooth surface or treat unpleasant sensations such as dentin hypersensitivity by laying a network of fibers over the tooth surface.
 
“The additional capital enables us to start launching Curodont Repair in various markets and to complete development of Curodont Protect. Working with dental professionals, credentis seeks to support with its product line a novel approach to caries treatment and prevention. Curodont Repair has its potential in the treatment of dental caries, whereas Curodont Protect has its main benefit in preventing tooth decay and in the treatment of dentin hypersensitivity!” explains CEO Dominik Lysek. The ultimate goal is to prevent caries by the use of its regenerative product line and frequent dental recalls by dentists and dental hygienists.
 
Credentis was founded in 2010 and is headquartered in the Technopark Aargau Switzerland, Windisch. credentis has won multiple startup awards including Swiss Venture Leader 2011 as well as support from startup organizations like Genilem and multiple public grants incl. Swiss National Fonds, Aargauer Forschungsfond and the Medical Technologies IKC together with the University of Leeds.
 

0Comments

More news about

Credentis AG

Company profiles on startup.ch

Credentis AG

rss